Rockefeller Capital Management L.P. Has $11.30 Million Stake in Relx Plc (NYSE:RELX)

Rockefeller Capital Management L.P. reduced its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 39.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 248,872 shares of the technology company's stock after selling 160,124 shares during the period. Rockefeller Capital Management L.P.'s holdings in Relx were worth $11,304,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in RELX. JPMorgan Chase & Co. increased its holdings in shares of Relx by 14.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company's stock valued at $39,225,000 after acquiring an additional 104,999 shares during the last quarter. LGT Group Foundation acquired a new stake in shares of Relx in the fourth quarter worth $257,000. Paradigm Asset Management Co. LLC boosted its holdings in shares of Relx by 17.1% during the 4th quarter. Paradigm Asset Management Co. LLC now owns 81,600 shares of the technology company's stock worth $3,706,000 after buying an additional 11,900 shares during the period. Smartleaf Asset Management LLC grew its stake in Relx by 120.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 12,066 shares of the technology company's stock valued at $548,000 after buying an additional 6,588 shares during the last quarter. Finally, Merit Financial Group LLC acquired a new position in Relx during the 4th quarter worth $301,000. Institutional investors and hedge funds own 15.02% of the company's stock.

Relx Stock Up 1.9 %

Shares of Relx stock traded up $1.00 during trading hours on Friday, reaching $52.20. 718,471 shares of the company's stock were exchanged, compared to its average volume of 716,903. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46. The company has a 50 day moving average of $49.37 and a two-hundred day moving average of $48.00. The stock has a market cap of $96.61 billion, a P/E ratio of 28.06, a P/E/G ratio of 2.73 and a beta of 0.84. Relx Plc has a fifty-two week low of $40.25 and a fifty-two week high of $52.54.

Relx Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be issued a dividend of $0.5586 per share. This represents a yield of 1.6%. This is an increase from Relx's previous semi-annual dividend of $0.23. The ex-dividend date is Friday, May 9th. Relx's payout ratio is presently 59.68%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. StockNews.com cut Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Morgan Stanley reiterated an "overweight" rating on shares of Relx in a research report on Wednesday. Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. Redburn Atlantic began coverage on shares of Relx in a research report on Wednesday, January 8th. They set a "buy" rating for the company. Finally, The Goldman Sachs Group started coverage on Relx in a research note on Wednesday, March 26th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy".

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.